In the last 50 years, no medical therapy has substantially improved the prognosis of non-small cell lung cancer (NSCLC) (Hansen, 1987) . The prognosis of metastatic NSCLC still remains poor, with median survival generally not greater than 20 weeks. Chemotherapy has a limited impact, and does not determine any evident benefit on the survival time. Therefore, these poor results justify the investigation of new medical strategies in the treatment of metastatic NSCLC, such as immunotherapy and hormonotherapy. Because of its fundamental role in the activation of an effective host antitumour immune response, interleukin-2 (IL-2) represents one of the most promising cytokines in the immune control of cancer growth (Grimm et al., 1982) . At present, very few results are available about the activity of IL-2 in NSCLC (Rosenberg et al., 1987; Ardizzoni et al., 1990; Krigel et al., 1991) . Preliminary data would suggest that IL-2, despite its biological efficacy in stimulating the immune system, has only a little activity, when it is given alone, in the treatment of advanced NSCLC. As far as the endocrine therapy is concerned, the hormonal approach in the treatment of NSCLC may be considered as a new interesting strategy on the basis of recent evidences, suggesting that lung cancer growth is stimulated by somatomedin-C (Minuto et al., 1988) , also termed insulin-like growth factor-I (IGF-I). At present, two different pharmacological approaches are available to reduce the endogenous IGF-I production, represented by somatostatin long-acting agonists (Lamberts, 1987) , and by the pineal hormone melatonin (MLT) (Smythe et al., 1974) . MLT has also appeared to exert a direct cytostatic action on some human cancer cell lines (Hill & Blask, 1988) and to induce tumour regressions in humans (Lissoni et al., 1989) . Moreover, MLT circadian secretion has been shown to play a fundamental role in maintaining an optimal immune performance (Maestroni et al., 1986) . Within its immunomodulating properties, MLT has been proven to antagonise the immunosuppression induced by adrenal steroids or chemotherapeutic agents (Maestroni et al., 1986) and to enhance the antitumour efficacy of IL-2 in some experimental conditions (Maestroni et al., 1990) . Preliminary clinical studies would suggest that MLT may induce a stabilisation of disease in a reasonable number of mestastatic NSCLC patients progressed under chemotherapy (Lissoni et al., 1989) , and to reduce some side-effects related to IL-2 immunotherapy of cancer .
On the basis of the potential importance of the pineal indole in the endocrine and immune control of lung cancer growth, we have designed an experimental neuroimmunotherapeutic regimen with IL-2 and MLT in the treatment of advanced NSCLC patients.
Materials and methods
The study included 20 consecutive metastatic NSCLC patients (M/F:14/6; median age 55 years, range 38-70), who were admitted to the Hospital of Monza to receive IL-2 plus MLT as a first line therapy of the metastatic disease. Eleven patients had been previously treated with surgery, while the other nine patients showed a metastatic disease at the time of the diagnosis of lung cancer. Eligibility criteria included: histologically proven NSCLC, metastatic disease, measureable lesions, no previous chemotherapy, age less than 70 years, and an expected survival greater than 3 months. Patients with second neoplasms, brain metastases or important cardiorespiratory diseases were not included in the study. The experimental protocol was explained to each patient, and informed consent was obtained. Histotype was adenocarcinoma in ten, epidermoid cell carcinoma in seven, and large cell carcinoma in the remaining three patients. Moreover, all patients had visceral lesions as dominant metastasis sites (lung: 11; lung plus liver, eight; liver: one).
MLT was supplied by Helsinn Chemicals SA (BreganzonaSwitzerland). Human recombinant IL-2 was supplied by Euro-Cetus (Amsterdam-Holland). MLT was given orally at a dose of 10 mg/daily at 8.00 pm, without interruption, starting 7 days before the onset of IL-2 injection. We decided to give MLT during the evening on the basis of experimental data, suggesting that the biological activity of the pineal hormone is greater when it is administered during the dark period of the day (Bartsch & Bartsch, 1981) . Moreover, a pretreatment with MLT was proposed on the basis of our previous experimental data, which showed that the maximum synergistic action may be achieved when MLT is given before the onset of IL-2 administration (Maestroni et al., 1990) . IL-2 was injected subcutaneously into different parts of the abdominal wall at a dose of 9 million IU m2 twice daily (8.00 am and 8.00 pm) for 2 days as an induction phase, followed by 3 million IU m-2 twice daily for 5 days/week for 4 consecutive weeks, corresponding to one cycle of therapy. In responder patients or in those with a stabilisation of disease, a second cycle was given after a rest period of 21 days, during which the only MLT was administered.
Radiological examinations were repeated after each cycle of therapy, then every 2 months. Liver metastases were investigated by CT scan. between epidermoid cell carcinoma and adenocarcinoma patients (2/7 vs 2/10). On the contrary, no tumour regression was seen in the three patients with large cell carcinoma. Ten patients (50%) achieved a s.d., with a median duration of 3.5+ months (range 2-7 months), without any significant relation to the histotype (adenocarcinoma: 6/10; epidermoid cell carcinoma: 4/7). The remaining 6/20 (30%) patients progressed after the first cycle of immunotherapy. The median overall survival time was 5+ months (2-14+).
Toxicity was accepted in all patients, and in particular no cardiovascular complication occurred during IL-2 administration. Fever higher than 38°C was seen in 11/20 patients, but it was generally limited to the first two days of IL-2 induction. The other toxicities were, as follows: vomiting grade 1-2: 3/20; anorexia 6/20; pruritus 3/20; depression: 2/20; nodules in the injection site: 7/20; hyperglycemia: 1/20. No patient had anaemia during IL-2 plus MLT therapy. Moreover, no patient showed a fall in platelet number; on the contrary, thrombocytosis higher than 1 million mm-3 occurred in one of the four responder patients. Platelet mean number progressively increased during the administration of IL-2 plus MLT, without, however, any significant difference between peak values and those seen before therapy (410,000 ± 60,000 vs 290,000 ± 40,000 mm-3; x-± s.e.).
The mean number of lymphocytes, T lymphocytes, NK cells and CD25-positive cells, as well as that of eosinophils, significantly increased during the administration of IL-2 plus MLT, as shown in Figure 1 . Eosinophilia greater than 20% occurred in 16/20 patients. Mean serum levels of neopterin and TNF significantly increased during IL-2 plus MLT therapy, with a peak on the first-second week of treatment (see Figure 2) . Finally, SIL-2R mean concentrations observed during therapy were significantly higher than those seen before, as illustrated in Figure 3 .
Discussion
This phase II study shows that the neuroimmunotherapeutic association between IL-2 and the pineal hormone MLT is able to induce objective tumour regressions in patients with advanced NSCLC, with clinical results comparable to those reported with chemotherapy (Hansen, 1987) . However, it has to be considered that the tumour regression obtained with an immunotherapeutic strategy depends on an activation of host immune antitumour response, whereas that achieved with chemotherapy is associated with a suppression of host immune defenses, induced by the antiblastic drugs themselves. The chemotherapy-induced damage of the immuno system would negatively influence the prognosis of cancer patients, and could explain the low survival time described in the literature in advanced NSCLC patients treated with chemotherapy, including the responders ones. The suppression of host defenses does not occur during the immunetherapy, which, in contrast, stimulates the generation of an effective anticancer reaction, with a potential benefit on the survival time. In fact, in agreement with the results previously reported in the literature with higher doses of IL-2 alone given intravenously (Ardizzoni et al., 1990; Krigel et al., 1991) , this study seems to suggest that IL-2 immunotherapy may determine a long survival time in advanced NSCLC patients, including those with liver metastases.
Objective tumour regression rate obtained in advanced NSCLC with IL-2 plus MLT seems to be clearly higher than that reported in literature with IL-2 alone, whose efficacy has appeared to be ranging between 0% (Ardizzoni et al., 1990) and 4% (Krigel et al., 1991 respect to other tumour histotypes, such as renal cancer and malignant melanoma (Rosenberg et al., 1987) , have still to be explained. However, they might depend at least in part on the documented inhibitory role of bronchoalveolar macrophages on NK cells and on other immune cells involved in the anticancer response (Bordignon et al., 1982) . The apparent enhancement of the clinical efficacy of IL-2 in NSCLC induced by the concomitant administration of the pineal hormone MLT might be due to a modulation of macrophage-mediated suppressive events which occur during IL-2 immunotherapy concomitantly to the activation of an effective immune response (Lissoni et al., 1991) . This hypothesis is supported by the lower increase of the macrophage marker neopterin and of SIL-2R during IL-2 plus MLT in respect to the values previously observed by ourselves with IL-2 alone (Lissoni et al., 1991) . On the contrary, the macrophage secretion of TNF, which is important in mediating tumour regression, does not seem to be negatively influenced by the concomitant administration of MLT. In our previous clinical studies with MLT alone in advanced NSCLC patients (Lissoni et al., 1989) , we observed an improvement in the survival time only in patients with lung, bone and soft tissue lesions as dominant metastasis sites, whereas no benefit was seen in the present of liver metastases; this study would suggest that the association between MLT and IL-2 may prolong the survival time also in patients with liver involvement. As far as the immunobiological effects are concerned, the increase in lymphocyte, T lymphocyte, NK cell and CD25-positive cell mean number obtained with IL-2 plus MLT seems to be comparable with that reported by other authors with IL-2 alone (Atzpodien et al., 1990) ; the only increase in eosinophil number seems to be more pronounced with IL-2 plus MLT than that obtained with IL-2 alone, by suggesting a possible synergistic action between MLT and cytokines involved in the stimulation of eosinophil production, such as interleukin-3 and interleukin-5.
In conclusion, this study shows that the neuroimmunotherapeutic regimen consisting of IL-2 plus MLT is an effective and well tolerated therapy in metastatic NSCLC, with results comparable to those obtained with chemotherapy, by representing a new possible therapeutic strategy in the treatment of disseminated lung cancer. Randomised studies with IL-2 vs IL-2 plus MLT will be needed to establish the impact of the pineal hormone MLT on the efficacy of IL-2 in NSCLC.
